Scholarlink

<p>Mutations or polymorphisms in <i>GRN</i>, encoding the CNS glycoprotein progranulin (PGRN), have been linked to several neurodegenerative diseases. In this study, we explored the role of PGRN in prion diseases. We observed that prion infection upregulated microglial PGRN expression. Following intracerebral inoculation with RML6 prions, <i>Grn</i><sup>-/-</sup> mice exhibited accelerated disease progression compared to <i>Grn</i><sup>+/-</sup> and <i>Grn</i><sup>+/+</sup> littermates. Histological analysis revealed augmented microglial activation in <i>Grn</i><sup>-/-</sup> mice. Temporal analysis revealed enhanced early microglial activation and prion clearance at 120 dpi, followed by excessive complement activation but inadequate clearance by 150 dpi. Additionally, <i>Grn</i><sup>-/-</sup> brains exhibited exacerbated astrogliosis and vacuolation. RNA-seq analysis indicated that complete PGRN deficiency in prion-infected mice shifted microglia from homeostatic to pro-inflammatory states. Notably, microglia-specific depletion of PGRN did not affect prion pathogenesis, suggesting that PGRN deficiency affects microglial activation and prion progression in a non-cell autonomous manner. These findings suggest that microglia respond to prion infection in a stepwise manner, and PGRN plays a critical role in modulating prion-induced microglial activation. Our results highlight the neuroprotective role of PGRN in prion disease and suggest that supplementation or boosting expression of PGRN could represent a promising therapeutic strategy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Ablation of progranulin augments microglial activation and accelerates prion progression

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月13日

查看全文
  • Bei Li,
  • Yiyue Shi,
  • Wenyu Hou,
  • Haoyuan Guan,
  • Jun Li,
  • Tuo Yi,
  • Wei Li,
  • Donglin Cai,
  • Petra Schwarz,
  • Adriano Aguzzi,
  • Caihong Zhu

摘要

Mutations or polymorphisms in GRN, encoding the CNS glycoprotein progranulin (PGRN), have been linked to several neurodegenerative diseases. In this study, we explored the role of PGRN in prion diseases. We observed that prion infection upregulated microglial PGRN expression. Following intracerebral inoculation with RML6 prions, Grn-/- mice exhibited accelerated disease progression compared to Grn+/- and Grn+/+ littermates. Histological analysis revealed augmented microglial activation in Grn-/- mice. Temporal analysis revealed enhanced early microglial activation and prion clearance at 120 dpi, followed by excessive complement activation but inadequate clearance by 150 dpi. Additionally, Grn-/- brains exhibited exacerbated astrogliosis and vacuolation. RNA-seq analysis indicated that complete PGRN deficiency in prion-infected mice shifted microglia from homeostatic to pro-inflammatory states. Notably, microglia-specific depletion of PGRN did not affect prion pathogenesis, suggesting that PGRN deficiency affects microglial activation and prion progression in a non-cell autonomous manner. These findings suggest that microglia respond to prion infection in a stepwise manner, and PGRN plays a critical role in modulating prion-induced microglial activation. Our results highlight the neuroprotective role of PGRN in prion disease and suggest that supplementation or boosting expression of PGRN could represent a promising therapeutic strategy.